STOCK TITAN
  1. Home
  2. Sec-filings
  3. NLSPW
  4. [6-K] NLS Pharmaceutics Ltd. Warrant Current Report (Foreign Issuer)

[6-K] NLS Pharmaceutics Ltd. Warrant Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock NLSPW logo
Nls Pharmaceutic

NASDAQ:NLSPW

NLSPW Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

NLSPW Latest News

Apr 15, 2025
NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models
Mar 31, 2025
NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement
Feb 27, 2025
NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform
Jan 30, 2025
NLS Pharmaceutics Announces the Submission of Three Research Abstracts to the 2025 ASCP Annual Meeting
Jan 28, 2025
NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence

NLSPW Latest SEC Filings

Aug 29, 2025
[6-K] NLS Pharmaceutics Ltd. Warrant Current Report (Foreign Issuer)
Aug 25, 2025
[6-K] NLS Pharmaceutics Ltd. Warrant Current Report (Foreign Issuer)
Aug 6, 2025
[6-K] NLS Pharmaceutics Ltd. Warrant Current Report (Foreign Issuer)
Jul 18, 2025
[6-K] NLS Pharmaceutics Ltd. Warrant Current Report (Foreign Issuer)
Jul 10, 2025
[D] NLS Pharmaceutics Ltd. Warrant SEC Filing

NLSPW Stock Data

3.16M
Biotechnology
Healthcare
Link
Switzerland
Zurich